BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 36416908)

  • 21. Utilizing 18F-fluoroethyltyrosine (FET) positron emission tomography (PET) to define suspected nonenhancing tumor for radiation therapy planning of glioblastoma.
    Hayes AR; Jayamanne D; Hsiao E; Schembri GP; Bailey DL; Roach PJ; Khasraw M; Newey A; Wheeler HR; Back M
    Pract Radiat Oncol; 2018; 8(4):230-238. PubMed ID: 29730279
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monitoring of radiochemotherapy in patients with glioblastoma using O-(2-¹⁸Fluoroethyl)-L-tyrosine positron emission tomography: is dynamic imaging helpful?
    Piroth MD; Liebenstund S; Galldiks N; Stoffels G; Shah NJ; Eble MJ; Coenen HH; Langen KJ
    Mol Imaging; 2013 Sep; 12(6):388-95. PubMed ID: 23981784
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Kinetic analysis and optimisation of
    Malaspina S; Oikonen V; Kuisma A; Ettala O; Mattila K; Boström PJ; Minn H; Kalliokoski K; Postema EJ; Miller MP; Scheinin M
    Eur J Nucl Med Mol Imaging; 2021 Oct; 48(11):3723-3731. PubMed ID: 33846844
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PET/MR in recurrent glioblastoma patients treated with regorafenib: [
    Lombardi G; Spimpolo A; Berti S; Campi C; Anglani MG; Simeone R; Evangelista L; Causin F; Zorzi G; Gorgoni G; Caccese M; Padovan M; Zagonel V; Cecchin D
    Br J Radiol; 2022 Jan; 95(1129):20211018. PubMed ID: 34762492
    [TBL] [Abstract][Full Text] [Related]  

  • 25. O-(2-[(18)F]fluoroethyl)-L-tyrosine uptake is an independent prognostic determinant in patients with glioma referred for radiation therapy.
    Sweeney R; Polat B; Samnick S; Reiners C; Flentje M; Verburg FA
    Ann Nucl Med; 2014 Feb; 28(2):154-62. PubMed ID: 24272067
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic value of early [18F]fluoroethyltyrosine positron emission tomography after radiochemotherapy in glioblastoma multiforme.
    Piroth MD; Pinkawa M; Holy R; Klotz J; Nussen S; Stoffels G; Coenen HH; Kaiser HJ; Langen KJ; Eble MJ
    Int J Radiat Oncol Biol Phys; 2011 May; 80(1):176-84. PubMed ID: 20646863
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intra-individual comparison of ¹⁸F-FET and ¹⁸F-DOPA in PET imaging of recurrent brain tumors.
    Kratochwil C; Combs SE; Leotta K; Afshar-Oromieh A; Rieken S; Debus J; Haberkorn U; Giesel FL
    Neuro Oncol; 2014 Mar; 16(3):434-40. PubMed ID: 24305717
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of the amino acid tracers 18F-FET and 18F-DOPA in high-grade glioma patients.
    Lapa C; Linsenmann T; Monoranu CM; Samnick S; Buck AK; Bluemel C; Czernin J; Kessler AF; Homola GA; Ernestus RI; Löhr M; Herrmann K
    J Nucl Med; 2014 Oct; 55(10):1611-6. PubMed ID: 25125481
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic Value of O-(2-[18F]-Fluoroethyl)-L-Tyrosine-Positron Emission Tomography Imaging for Histopathologic Characteristics and Progression-Free Survival in Patients with Low-Grade Glioma.
    Bette S; Gempt J; Delbridge C; Kirschke JS; Schlegel J; Foerster S; Huber T; Pyka T; Zimmer C; Meyer B; Ringel F
    World Neurosurg; 2016 May; 89():230-9. PubMed ID: 26855307
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic value of subventricular zone involvement in relation to tumor volumes defined by fused MRI and O-(2-[
    Harat M; Małkowski B; Roszkowski K
    Radiat Oncol; 2019 Mar; 14(1):37. PubMed ID: 30832691
    [TBL] [Abstract][Full Text] [Related]  

  • 31.
    Michaud L; Beattie BJ; Akhurst T; Dunphy M; Zanzonico P; Finn R; Mauguen A; Schöder H; Weber WA; Lassman AB; Blasberg R
    Eur J Nucl Med Mol Imaging; 2020 Jun; 47(6):1353-1367. PubMed ID: 31418054
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epileptic Activity Increases Cerebral Amino Acid Transport Assessed by 18F-Fluoroethyl-l-Tyrosine Amino Acid PET: A Potential Brain Tumor Mimic.
    Hutterer M; Ebner Y; Riemenschneider MJ; Willuweit A; McCoy M; Egger B; Schröder M; Wendl C; Hellwig D; Grosse J; Menhart K; Proescholdt M; Fritsch B; Urbach H; Stockhammer G; Roelcke U; Galldiks N; Meyer PT; Langen KJ; Hau P; Trinka E
    J Nucl Med; 2017 Jan; 58(1):129-137. PubMed ID: 27469356
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of O-(2-18F-fluoroethyl)-L-tyrosine PET and 3-123I-iodo-alpha-methyl-L-tyrosine SPECT in brain tumors.
    Pauleit D; Floeth F; Tellmann L; Hamacher K; Hautzel H; Müller HW; Coenen HH; Langen KJ
    J Nucl Med; 2004 Mar; 45(3):374-81. PubMed ID: 15001676
    [TBL] [Abstract][Full Text] [Related]  

  • 34.
    Albano D; Tomasini D; Bonù M; Giubbini R; Bertagna F
    Ann Nucl Med; 2020 Feb; 34(2):81-86. PubMed ID: 31773466
    [No Abstract]   [Full Text] [Related]  

  • 35. Matched-Pair Comparison of
    Kroenke M; Mirzoyan L; Horn T; Peeken JC; Wurzer A; Wester HJ; Makowski M; Weber WA; Eiber M; Rauscher I
    J Nucl Med; 2021 Aug; 62(8):1082-1088. PubMed ID: 33277394
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of F-18-labeled amino acid derivatives and [18F]FDG as PET probes in a brain tumor-bearing animal model.
    Wang HE; Wu SY; Chang CW; Liu RS; Hwang LC; Lee TW; Chen JC; Hwang JJ
    Nucl Med Biol; 2005 May; 32(4):367-75. PubMed ID: 15878506
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An interindividual comparison of O-(2-[18F]fluoroethyl)-L-tyrosine (FET)- and L-[methyl-11C]methionine (MET)-PET in patients with brain gliomas and metastases.
    Grosu AL; Astner ST; Riedel E; Nieder C; Wiedenmann N; Heinemann F; Schwaiger M; Molls M; Wester HJ; Weber WA
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1049-58. PubMed ID: 21570201
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment-Related Uptake of
    Geisler S; Stegmayr C; Niemitz N; Lohmann P; Rapp M; Stoffels G; Willuweit A; Galldiks N; Filss C; Sabel MC; Coenen HH; Shah NJ; Langen KJ
    J Nucl Med; 2019 Oct; 60(10):1373-1379. PubMed ID: 30850492
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of O-(2-
    Verger A; Filss CP; Lohmann P; Stoffels G; Sabel M; Wittsack HJ; Kops ER; Galldiks N; Fink GR; Shah NJ; Langen KJ
    World Neurosurg; 2018 May; 113():e727-e737. PubMed ID: 29510293
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative Preclinical Biodistribution, Dosimetry, and Endoradiotherapy in Metastatic Castration-Resistant Prostate Cancer Using
    Yusufi N; Wurzer A; Herz M; D'Alessandria C; Feuerecker B; Weber W; Wester HJ; Nekolla S; Eiber M
    J Nucl Med; 2021 Aug; 62(8):1106-1111. PubMed ID: 33443072
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.